<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018199</url>
  </required_header>
  <id_info>
    <org_study_id>UFMG-PCT</org_study_id>
    <nct_id>NCT01018199</nct_id>
  </id_info>
  <brief_title>Procalcitonin Versus C-reactive Protein to Guide Therapy in Community Acquired Pneumonia</brief_title>
  <acronym>CAP-Marker</acronym>
  <official_title>Use of Procalcitonin (PCT) and C-reactive Protein (CRP) to Guide Antibiotic Therapy in Community Acquired Pneumonia: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Minas Gerais</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of Minas Gerais</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators aim to test if C-reactive protein (CRP) or procalcitonin(PCT)&#xD;
      - guided strategy allows to reduce the antibiotic use in patients wiht community-acquired&#xD;
      pneumonia. Therefore, the safety of this intervention will be carefully measured.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods&#xD;
&#xD;
      • Patients and settings:&#xD;
&#xD;
      All adult (&gt; 18 years old) patients with diagnosis community-acquired pneumonia will receive&#xD;
      initial antibiotic therapy based on local guidelines and susceptibility patterns, according&#xD;
      to the decision of the treating physician.Patients will be randomly assigned to one of two&#xD;
      groups, which respectively include PCR and PCT clinical procedure protocol. Randomization&#xD;
      will be done using a table of random numbers generated by computer. For practical reasons the&#xD;
      doctors treating the patients in question have science group in which the patient was&#xD;
      included.&#xD;
&#xD;
      Patients included in the two groups will have baseline assessment during the first day of&#xD;
      study:&#xD;
&#xD;
        -  Clinical evaluation of basic&#xD;
&#xD;
        -  Start of antibiotic therapy&#xD;
&#xD;
        -  Inclusion in the study&#xD;
&#xD;
        -  Randomization (after signing the Informed Consent)&#xD;
&#xD;
        -  Interventions:&#xD;
&#xD;
      They will have circulating PCT and CRP levels measured at baseline and days 1,2,3 e 5 in both&#xD;
      groups.&#xD;
&#xD;
      Group 1 - CRP group: the duration of antibiotic therapy will be based on circulating CRP&#xD;
      levels.&#xD;
&#xD;
      Group 2 - PCT group: the duration of antibiotic therapy will be based on circulating PCT&#xD;
      levels.&#xD;
&#xD;
      Patients enrolled in the study will undergo daily measurements of plasma CRP (Dry Chemistry -&#xD;
      Johnsons &amp; Johnsons) and PCT (BRAHMS PCT VIDAS) levels up to day 5, and then, every 48hr in&#xD;
      patients remaining in the ICU, and every 5 days in those transferred to the ward. Patients&#xD;
      will be followed up 28 days, or until death or hospital transference, which comes first. PCT&#xD;
      and CRP results will be released in sealed envelopes. During the study period, only the&#xD;
      results corresponding to the patient randomization group will be open; i.e., CRP for CRP&#xD;
      group patients and PCT for PCT group patients.&#xD;
&#xD;
      Criteria for antibiotic interruption:&#xD;
&#xD;
      The investigators will propose the interruption of antibiotics if:&#xD;
&#xD;
        1. The patients is clinically stable, without signs of active infection&#xD;
&#xD;
        2. CRP group: a relative reduction of 50% in baseline CRP levels, or a value lower than&#xD;
           25mg/dl is reached.&#xD;
&#xD;
        3. PCT group: a relative reduction of 90% in baseline PCT levels, or if a absolute value&#xD;
           lower than 0.1 ng/ml is reached.&#xD;
&#xD;
      The final decision regarding antibiotic therapy will be always let to the discretion of the&#xD;
      treating physician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Changes in the profile of patients assisted by the hospital&#xD;
  </why_stopped>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of antibiotic therapy for the first episode of infection</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total antibiotic exposure days per 1,000 days</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Days alive without antibiotics</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause 28-day mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical cure rate</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection relapse (diagnosed less than 48h after antibiotic discontinuation)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization stay</measure>
    <time_frame>Whole hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nosocomial infection rate</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nosocomial superinfection (diagnosed more than 48hous after discontinuation of the antibiotic therapy given to the first episode of infection)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isolation of resistant bacteria</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause 90-day mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>costs of hospitalization</measure>
    <time_frame>Whole hospitalization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Group 1- C-reactive protein (CRP) guided antibiotic therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention on antibiotic therapy will be based on circulating RCP levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - procalcitonin (PCT) guided antibiotic therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention on antibiotic therapy will be based on circulating PCT levels</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CRP</intervention_name>
    <description>C-reactive protein guided antibiotic therapy plasma CRP measurement to guide the duration of antibiotic therapy</description>
    <arm_group_label>Group 1- C-reactive protein (CRP) guided antibiotic therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PCT</intervention_name>
    <description>Procalcitonin guided antibiotic therapy plasma PCT measurement to guide the duration of antibiotic therapy</description>
    <arm_group_label>Group 2 - procalcitonin (PCT) guided antibiotic therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Signed informed consent&#xD;
&#xD;
          3. Suspected or confirmed community-acquired pneumonia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Nosocomial pneumonia: development of symptoms after 48 hours of admission to the&#xD;
             Emergency Department, or within 14 days after hospital discharge&#xD;
&#xD;
          2. Patients with lung cancer confirmed strongly suspected.&#xD;
&#xD;
          3. Patients with severe immunosuppression, such as severe neutropenia (&lt;500&#xD;
             neutrófilos/mm3), use of corticosteroids in doses above 0.5 mg / kg / day of&#xD;
             prednisone or equivalent for at least 2 weeks, transplantation of solid organs or&#xD;
             cells hematopoietic, use of immunosuppressants for any other reason (eg. azathioprine&#xD;
             or cyclosporine), hipogamagloulinemia&#xD;
&#xD;
          4. Patients with asplenia in any order&#xD;
&#xD;
          5. Pregnant&#xD;
&#xD;
          6. Patients with known HIV infection&#xD;
&#xD;
          7. Stay indicated only for social reasons&#xD;
&#xD;
          8. Patients on antibiotics for any other reason&#xD;
&#xD;
          9. Patients with multiple trauma, burns or surgery grid size in the last 5 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vandack A Nobre, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical School of the Federal University of Minas Gerais</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karla F Finotti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical School of the Federal University of Minas Gerais</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital das Clínicas - Universidade Federal de Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>November 20, 2009</study_first_submitted>
  <study_first_submitted_qc>November 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2009</study_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Minas Gerais</investigator_affiliation>
    <investigator_full_name>Vandack Alencar Nobre</investigator_full_name>
    <investigator_title>Associate Professor, PhD</investigator_title>
  </responsible_party>
  <keyword>C-reactive protein</keyword>
  <keyword>procalcitonin</keyword>
  <keyword>community-acquired pneumonia</keyword>
  <keyword>antibiotic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

